Survival analysis after intramedullary stabilization for metastatic disease of the femur: prognostic value of common laboratory parameters

2020 ◽  
Author(s):  
James E. Willoughby ◽  
Joseph F. Baker
Keyword(s):  
Survival Analysis ◽  
Metastatic Disease ◽  
Prognostic Value ◽  
Laboratory Parameters ◽  
Intramedullary Stabilization ◽  
Common Laboratory

Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinomas.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 388-388 ◽  
Author(s):  
D. S. Serna ◽  
L. K. Martin ◽  
X. Li ◽  
L. M. Weatherby ◽  
J. S. Rose ◽  
...  
Keyword(s):  
Overall Survival ◽  
Survival Analysis ◽  
Metastatic Disease ◽  
Prognostic Value ◽  
Colorectal Adenocarcinoma ◽  
Mutation Status ◽  
Kaplan Meier ◽  
Mutational Status ◽  
Colorectal Adenocarcinomas ◽  
Kras Mutation Status

388 Background: Mutations in the KRAS oncogene are present in approximately 30-40% of colorectal adenocarcinomas. Wild-type (WT) KRAS mutational status is recognized to be predictive of tumor response with epidermal growth factor receptor-directed therapies such as cetuximab and panitumumab. Studies evaluating the prognostic value of KRAS status in localized (stage II and III) disease have been contradictory. The prognostic value in metastatic disease, either synchronous or metachronous, is less studied. Methods: Consecutive patients with metastatic colorectal adenocarcinoma underwent tumor testing for KRAS exon 2 (codons 12 and 13) mutations by polymerase chain reaction amplification and direct nucleotide sequencing. The clinical characteristics, treatments, and outcomes of these patients were then retrospectively analyzed, stratified by synchronous or metastatic disease and KRAS mutational status (WT or mutated). Results: For synchronous metastatic disease, KRAS WT patients (n = 39) had median overall survival (OS) of 34.3 months (95% CI, 21.8-58.3). KRAS mutated patients (n = 24) had median OS of 40.3 months (95% CI, 25.7-51.0; log-rank p = 0.55). By Kaplan-Meier survival analysis, 3-year OS was 48.9% (95% CI, 31.1-64.5) for KRAS WT and 51.1% (95% CI, 27.6-70.6) for KRAS mutated patients. Five-year OS was 27.8% (95% CI, 11.6-46.8) for KRAS WT and 9.7% (95% CI, 0.7-33.8) for KRAS mutated patients. For metachronous metastatic disease, from time of development of metastasis, KRAS WT patients (n = 29) had median OS of 33.2 months (95% CI, 28.3-40.7). KRAS mutated patients (n = 16) had median OS of 53.0 months (95% CI, 27.8-not applicable; log-rank p = 0.29). By Kaplan-Meier survival analysis, 3-year OS was 40.1% (95% CI, 19.9-59.7) for KRAS WT and 57.3% (95% CI, 25.0-80.0) for KRAS mutated patients. Five-year OS was 22.9% (95% CI, 7.6-43.2) for KRAS WT and 28.6% (95% CI, 1.7-68.1) for KRAS mutated patients. Conclusions: KRAS mutation status does not influence overall survival in either synchronous or metachronous metastatic colorectal adenocarcinoma. No significant financial relationships to disclose.

scholarly journals The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Chengquan Shen ◽  
Jing Liu ◽  
Jirong Wang ◽  
Xiaokun Yang ◽  
Haitao Niu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
T Cells ◽  
Survival Analysis ◽  
Prognostic Value ◽  
Molecular Mechanisms ◽  
Tyrosine Phosphatase ◽  
Gene Set Enrichment Analysis ◽  
Expression Level ◽  
Pathologic Features ◽  
The Relationship

PTPN6 (protein tyrosine phosphatase nonreceptor type 6), a tyrosine phosphatase, is known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. Previous studies have demonstrated that PTPN6 expression is relatively elevated in several malignancies. However, the role of PTPN6 in bladder cancer (BC) remains unclear. The purpose of this study was to explore the prognostic value of PTPN6 in BC. RNA-seq data from The Cancer Genome Atlas (TCGA) was used to identify the expression level of PTPN6 in BC. The relationship between clinical pathologic features and PTPN6 were analyzed with the Wilcoxon signed-rank test. The prognostic and predictive value of PTPN6 was evaluated by survival analysis and nomogram. Gene Set Enrichment Analysis (GSEA) was conducted to explore the potential molecular mechanisms of PTPN6 in BC. Finally, Tumor Immune Estimation Resource (TIMER) was applied to investigate the relationship between PTPN6 and immune cell infiltration in the tumor microenvironment. Results indicated that PTPN6 was overexpressed in BC tissues compared with normal bladder tissues and was significantly correlated with grade, stage, T, and N. Survival analysis showed that low expression of PTPN6 was significantly related to the poor overall survival (OS) in BC patients. Coexpression analysis showed that PTPN6 and TNFRSF14 (Tumor necrosis factor receptor superfamily member 14) have a close correlation in BC. GSEA showed that multiple cancer-associated signaling pathways are differentially enriched in the PTPN6 high expression phenotype. Moreover, the expression level of PTPN6 was positively associated with the infiltration of B cells, CD4+T cells, dendritic cells, and neutrophils and negatively associated with CD8+ T cells and macrophages in BC. In conclusion, we identified that PTPN6 may be a novel prognostic biomarker in BC based on the TCGA database. Further clinical trials are needed to confirm our observations and mechanisms underlying the prognostic value of PTPN6 in BC also deserve further experimental exploration.

A Study on Different Common Laboratory Parameters among Malaria Cases at Alluri Sita Ramaraju Academy of Medical Sciences, Eluru, and Andhra Pradesh

2016 ◽  
Vol 7 (2) ◽  
pp. 215
Author(s):  
Shiva Gautham Teja Sunkarapalli ◽  
Sukaveni Votturu ◽  
K Chandra Sekhar ◽  
Gambhir Swarnalatha Devi ◽  
P G Deotale
Keyword(s):  
Andhra Pradesh ◽  
Medical Sciences ◽  
Laboratory Parameters ◽  
Common Laboratory

Prognostic Value of Microvascular Invasion in Predicting the Cancer Specific Survival and Risk of Metastatic Disease in Renal Cell Carcinoma: A Multicenter Investigation

2012 ◽  
Vol 187 (2) ◽  
pp. 418-423 ◽  
Author(s):  
Nils Kroeger ◽  
Edward N. Rampersaud ◽  
Jean-Jacques Patard ◽  
Tobias Klatte ◽  
Frédéric D. Birkhäuser ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Disease ◽  
Renal Cell ◽  
Prognostic Value ◽  
Microvascular Invasion ◽  
Cancer Specific Survival

scholarly journals Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases

Blood ◽  
1982 ◽  
Vol 59 (5) ◽  
pp. 1001-1005
Author(s):  
C Rozman ◽  
E Montserrat ◽  
E Feliu ◽  
A Granena ◽  
P Marin ◽  
...  
Keyword(s):  
Survival Analysis ◽  
Chronic Lymphocytic Leukemia ◽  
Prognostic Value ◽  
International Workshop ◽  
Risk Groups ◽  
Multiple Regression Model ◽  
Lymphocytic Leukemia ◽  
Multivariate Survival Analysis ◽  
Single Institution ◽  
Multivariate Survival

A multivariate survival analysis by means of Cox's multiple regression model was performed on a series of 150 consecutive patients with chronic lymphocytic leukemia (CLL) from a single institution. In addition to the well established prognostic factors, such as anemia and thrombocytopenia, a marked prognostic value of the degree of absolute peripheral lymphocytosis emerged from this analysis. This was evident in the whole population as well as in low and intermediate risk groups of patients (Rai's stages 0, I, and II and International Workshop on CLL stages A and B), pointing out that different subsets of patients can be isolated within these groups.

scholarly journals Prognostic Value of Dysnatremia in COVID-19 Disease

2021 ◽  
Author(s):  
Şeyma Kayhan Ömeroğlu ◽  
Mehmet Burak Öztop
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Mortality Rate ◽  
Prognostic Value ◽  
Ventilatory Support ◽  
Predictive Marker ◽  
Inpatient Mortality ◽  
Treatment Need ◽  
Laboratory Parameters ◽  
Icu Treatment

Objective: The infection of Corona 2019 (COVID-19) had first diagnosed in December 2019 and evolved into a worldwide pandemic in March 2020. In Turkey first diagnose was announced in March 2020. Low costed and easily accessible laboratory parameters needed for predicting the prognosis of this disease as its outcome pattern vary greatly from patient to patient. There is promising data on predicting the outcomes with disnatremic results. Methods: In this study we retrospectively investigated all adults with the diagnosis of COVID-19 who attended to Turkan Ozilhan Hospital over a 3 months period. We evaluated the relation of dysnatremia (hyponatremia as <135 mmol/L or hypernatremia as >145 mmol/L) for need of intensive care unit (ICU) treatment, need of intubation for mechanic ventilatory support and inpatient mortality. Results: one thousand seventy tree patients with COVID-19 [53..9% males (793 patients) and 46.1% females (680 patients), were investigated for this study. Their median age was 53.9 years ranging betweent 19-94. The dysnatremic groups had significantly higher rates of need for ICU and intubation The need for ICU was 89 (21.5%) patients in normonatremic group but 38 (76%) patients in hypernatremic and 71 (64%) in hyponatremic patients (p<0.01 for each of them). The mortality rate was 5% in normonatremic patients but 50% in hypernatremic and 28% in hyponatremic patients (p<0.01 for each of them). Conclusion: In this study we aimed to draw attention to the importance of abnormal sodium levels as a predictive marker in COVID-19. In small town hospitals the physicians should be aware of the risks of disnatremic patients with COVID-19 and take precautions while treating them.

scholarly journals Integrated analysis of autophagy-related genes(ATGs) reveals the prognostic value of oral squamous cell carcinoma

2020 ◽  
Author(s):  
Guangzhao Huang ◽  
Zhi-yun Li ◽  
Yu Rao ◽  
Xiao-zhi Lv
Keyword(s):  
Survival Analysis ◽  
Signaling Pathway ◽  
Risk Score ◽  
Prognostic Value ◽  
Risk Model ◽  
Cox Regression ◽  
Expression Profiles ◽  
Differentially Expressed ◽  
Integrated Analysis ◽  
Score Model

Abstract Background: Increasing evidence demonstrated that autophagy paly a crucial role in initiation and progression of OSCC. The aim of this study was to explore the prognostic value of autophagy-related genes(ATGs) in patients with OSCC. RNA-seq and clinical data were downloaded from TCGA database following extrating ATGs expression profiles. Then, differentially expressed analysis was performed in R software EdgeR package, and the potential biological function of differentially expressed ATGs were explored by GO and KEGG enrichment analysis. Furthermore, a risk score model based on ATGs was constructed to predict the overall survival. Moreover, univariate, multivariate cox regression and survival analysis were used to select autophagy related biomarkers which were identified by RT-qPCR in OSCC cell lines, OSCC tissues and matched normal mucosal tissues. Results: Total of 232 ATGs were extrated and 37 genes were differentially expressed in OSCC. GO and KEGG analysis indicated that these differentially expressed genes were mainly located in autophagosome membrane, and associated with apoptosis, platinum drug resistance, ErbB signaling pathway and TNF signaling pathway. Furthermore, a risk score model including 9 variables was constructed and subsequently identified with univariate, multivariate cox regression, survival analysis and Receiver Operating Characteristic curve(ROC). Moreover, ATG12 and BID were identified as potential autophagy related biomakers. Conclusion: This study successfully constructed a risk model to predict the prognosis of patients with OSCC, and the risk score may be as a independent prognostic biomarker in OSCC. ATG12 and BID were identified as potential biomarkers in tumor diagnosis and treatment of OSCC.

Sign in / Sign up

Export Citation Format

Share Document